

Supporting Information

NBS-Promoted Halosulfonylation of Terminal Alkynes: Highly Regio- and Stereoselective Synthesis of (E)- β -Halo Vinylsulfones

Yang Gao, Wanqing Wu,* Yubing Huang, Kefan Huang, Huanfeng Jiang*

School of Chemistry and Chemical Engineering, South China University of Technology,
Guangzhou 510640, China

E-mail: jianghf@scut.edu.cn, cewuwq@scut.edu.cn; *Fax and Tel.:* (+86) 20-87112906


Table of Contents

General Information.....	2
Control Experiments.....	2
Analysis Data for Compounds 3aa-3ga, 4a-6a	4
NMR Spectra for Compounds 3aa-3ga, 4a-6a	9


General Information

^1H and ^{13}C NMR spectra were recorded on BRUKER DRX-400 spectrometer using CDCl_3 as solvent and TMS as an internal standard. Gas chromatograph mass spectra were obtained with a SHIMADZU model GC-MS-QP5000 spectrometer. High-resolution mass spectra (ESI) were obtained with a LCMS-IT-TOF mass spectrometer. IR spectra were obtained as potassium bromide pellets or as liquid films between two potassium bromide pellets with a Bruker Vector 22 spectrometer. TLC was performed using commercially prepared 100-400 mesh silica gel plates (GF_{254}), and visualization was effected at 254 nm. Unless otherwise stated, all reagents and solvents were purchased from commercial suppliers and used without further purification.


Control Experiments




First, two deuterated experiments were carried out to distinguish the hydrogen position of the terminal alkyne. As depicted in [eqn. (1)], deuterium product $3\text{aa}'$ was obtained exclusively in 86% isolated yield and the deuterium atom (98% examined by ^1H NMR spectroscopy) was still present. When 0.1 mL D_2O was added, there was no deuterium in the halosulfonation product and deuterium pyrrolidine-2,5-dione was detected by GC-MS [eqn. (2)].



Radical-trapping Experiments^a

$\text{Ph}-\text{C}\equiv\text{C}-\text{H} \quad + \quad \text{C}_6\text{H}_4\text{SO}_2\text{Na} \xrightarrow[\text{radical scavenger}]{\text{NBS}}$		 3aa, -
Scavenger	Yield ^b (%)	
none	88	
TMEPO (1.2 equiv)	0	
BHT (1.2 equiv)	0	

^a Radical-trapping experiments were carried out by adding 1.2 equiv radical scavengers TEMPO and BHT in the reaction system under the standard reaction condition. ^b Determined by GC based on **1a**. TEMPO = (2,2,6,6-tetramethylpiperidin-1-yl)oxyl. BHT = 2,6-di-tert-butyl-4-methylphenol.



When ethene-1,1-diyl dibenzene was employed as the substrate under the standard reaction conditions, (2-tosylethene-1,1-diyl)dibenzene was produced in good yield, thus providing an evidence for this radical process.

Analysis Data for Compounds 3aa-3ga, 4a-6a

(E)-1-(2-bromo-2-phenylvinylsulfonyl)-4-methylbenzene (3aa) ¹

white solid (142.8 mg, 85%); mp 97–99 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 8.2 Hz, 2H), 7.36 (dd, *J* = 8.5, 4.1 Hz, 1H), 7.31 (d, *J* = 4.4 Hz, 4H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.14 (s, 1H), 2.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 138.2, 137.3, 136.0, 134.2, 130.2, 129.6, 128.5, 127.8, 127.7, 21.48.

(E)-1-(2-bromo-2-(4-fluorophenyl)vinylsulfonyl)-4-methylbenzene (3ab) ¹

white solid (145.1 mg, 82%); mp 90–91 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, *J* = 8.2 Hz, 2H), 7.39 – 7.30 (m, 2H), 7.23 (d, *J* = 8.1 Hz, 2H), 7.13 (s, 1H), 7.02 (t, *J* = 8.6 Hz, 2H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 163.6 (d, *J* = 250.5 Hz), 144.8, 137.2, 136.8, 134.5, 132.0 (d, *J* = 3.4 Hz), 130.9 (d, *J* = 8.8 Hz), 129.7, 127.77, 115.1 (d, *J* = 22 Hz), 21.5.

(E)-1-(2-bromo-2-(4-chlorophenyl)vinylsulfonyl)-4-methylbenzene (3ac) ¹

white solid (149.8 mg, 81%); mp 119–120 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, *J* = 8.2 Hz, 2H), 7.34 – 7.27 (m, 4H), 7.26 – 7.24 (m, 2H), 7.12 (s, 1H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.94, 137.28, 136.66, 136.53, 134.73, 134.47, 130.03, 129.79, 128.30, 127.82, 21.63.

(E)-1-bromo-4-(1-bromo-2-tosylvinyl)benzene (3ad) ¹

white solid (165.6 mg, 80%); mp 133–135 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, *J* = 8.3 Hz, 2H), 7.50 – 7.45 (m, 2H), 7.22 (tt, *J* = 4.1, 2.6 Hz, 4H), 7.12 (s, 1H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.9, 137.2, 136.5, 134.9, 134.8, 131.2, 130.2, 129.8, 127.8, 125.0, 21.6.

(E)-1-(2-bromo-2-p-tolylvinylsulfonyl)-4-methylbenzene (3ae) ¹

white solid (154.0 mg, 88%); mp 121–122 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.52 (d, *J* = 8.0 Hz, 2H), 7.25 (d, *J* = 7.7 Hz, 2H), 7.21 (d, *J* = 8.0 Hz, 2H), 7.14 (d, *J* = 7.8 Hz, 2H), 7.08 (s, 1H), 2.40 (s, 3H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.6, 140.9, 138.6, 137.6, 133.6, 133.2, 129.6, 128.76, 128.6, 127.8, 21.6, 21.4.

(E)-1-(2-bromo-2-(4-tert-butylphenyl)vinylsulfonyl)-4-methylbenzene (3af)

white solid (156.8 mg, 80%); mp 107–108 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.3 Hz, 2H), 7.32 – 7.29 (m, 2H), 7.26 – 7.22 (m, 2H), 7.14 (t, *J* = 4.0 Hz, 3H), 2.37 (s, 3H), 1.33 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 153.9, 144.3, 138.6, 137.4, 134.2, 133.0, 129.4, 128.6, 127.8, 124.9, 34.8, 31.2, 21.5. IR (KBr, cm⁻¹): 3046, 2961, 1601, 1320, 1149, 828, 651, 555; ESI-HRMS calcd for C₁₉H₂₁BrO₂S (M + Na)⁺ 415.0338; found, 415.0336.

(E)-1-methoxy-4-(2-tosylvinyl)benzene (3ag) ¹

white solid (150.1 mg, 82%); mp 110–111 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, *J* = 8.3 Hz, 2H), 7.35 – 7.32 (m, 2H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.06 (s, 1H), 6.86 – 6.83 (m, 2H), 3.84 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 161.4, 144.5, 138.6, 137.7, 133.1, 130.8, 129.6, 128.2, 127.7, 113.3, 55.4, 21.6.

(E)-4-(1-bromo-2-tosylvinyl)biphenyl (3ah)

white solid (173.0 mg, 84%); mp 123–124 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.63 – 7.56 (m, 2H), 7.56 – 7.51 (m, 4H), 7.46 (dd, *J* = 10.2, 4.7 Hz, 2H), 7.40 (dd, *J* = 7.7, 5.9 Hz, 3H), 7.19 (t, *J* = 6.6 Hz, 2H), 7.16 (s, 1H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.6, 143.3, 139.9, 138.0, 137.4, 134.8, 134.3, 133.2, 129.6, 129.2, 128.9, 127.8, 127.1, 126.5, 21.6. IR (KBr, cm⁻¹): 3047, 2924, 2177, 1600, 1485, 1324, 1152, 1085, 760, 551; ESI-HRMS calcd for C₂₁H₁₇BrO₂S (M + Na)⁺ 435.0025; found, 435.0019.

(E)-1-(1-bromo-2-tosylvinyl)-3-methylbenzene (3ai)

white solid (150.5 mg, 86%); mp 102–104 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, *J* = 8.3 Hz, 2H), 7.22 – 7.16 (m, 4H), 7.12 (t, *J* = 3.4 Hz, 2H), 7.02 (s, 1H), 2.39 (s, 3H), 2.31 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 138.6, 137.7, 136.0, 134.3, 131.1, 129.5, 128.9, 127.9, 127.8, 125.7, 21.5, 21.2. IR (KBr, cm⁻¹): 3046, 1594, 1322, 1149, 1085, 930, 793, 694, 553; ESI-HRMS calcd for C₁₆H₁₅BrO₂S (M + Na)⁺ 372.9868; found, 372.9864.

(E)-1-(1-bromo-2-(phenylsulfonyl)vinyl)-2,4-dimethylbenzene (3aj)

white solid (145.6 mg, 80%); mp 97–99 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.42 (d, *J* = 8.3 Hz, 2H), 7.21 – 7.16 (m, 3H), 6.98 – 6.92 (m, 3H), 2.40 (s, 3H), 2.34 (s, 3H), 2.07 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.6, 140.3, 138.8, 137.3, 135.3, 132.7, 130.9, 129.9, 129.5, 127.9, 127.2, 126.2, 21.6, 21.3, 19.1. IR (KBr, cm⁻¹): 3045, 2357, 2169, 1605, 1449, 1325, 1150, 1084, 814, 550; ESI-HRMS calcd for C₁₇H₁₇BrO₂S (M + Na)⁺ 387.0025; found, 387.0022.

(E)-3-(1-bromo-2-tosylvinyl)pyridine (3ak)

white solid (128.1 mg, 76%); mp 115–116 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.61 (d, *J* = 36.1 Hz, 2H), 7.76 – 7.72 (m, 1H), 7.56 (d, *J* = 8.3 Hz, 2H), 7.35 (dd, *J* = 7.8, 4.8 Hz, 1H), 7.30 – 7.27 (m, 2H), 7.24 (s, 1H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 150.8, 148.3, 145.2, 137.1, 136.2, 135.9, 134.0, 130.0, 127.8, 122.8, 21.63. IR (KBr, cm⁻¹): 3049, 2358, 2170, 1605, 1450, 1318, 1150, 1086, 815, 552; ESI-HRMS calcd for C₁₄H₁₂BrNO₂S (M + H)⁺ 337.9845; found, 337.9836.

(E)-1-(2-bromooct-1-enylsulfonyl)-4-methylbenzene (3al) ¹

colorless oil (132.4 mg, 77%); ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.3 Hz, 2H), 7.36 (d, *J* = 8.0 Hz, 2H), 6.75 (s, 1H), 3.10 – 2.90 (m, 2H), 2.45 (s, 3H), 1.58 (dt, *J* = 15.0, 7.4 Hz, 2H), 1.39 – 1.20 (m, 6H), 0.90 (dd, *J* = 9.3, 4.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 146.7, 144.8, 138.2, 132.1, 130.0, 127.4, 36.8, 31.4, 28.4, 28.3, 22.4, 21.6, 14.0.

(E)-5-bromo-6-tosylhex-5-enenitrile (3am)

colorless oil (140.6 mg, 86%); ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 8.3 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 2H), 6.83 (s, 1H), 3.26 – 3.18 (m, 2H), 2.48 – 2.44 (m, 5H), 2.04 (p, *J* = 7.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 145.3, 142.3, 137.6, 134.0, 130.2, 127.5, 118.8, 35.6, 24.3, 21.7, 16.2. IR (KBr, cm⁻¹): 3045, 2357, 2169, 1605, 1419, 1270, 1148, 1079, 754, 545; ESI-HRMS calcd for C₁₃H₁₄BrNO₂S (M + Na)⁺ 349.9821; found, 349.9816.

(E)-(2-bromo-2-cyclohexylvinylsulfonyl)benzene (3an)

colorless oil (138.5 mg, 81%); ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 8.3 Hz, 2H), 7.36 (d, *J* = 8.0 Hz, 2H), 6.72 (s, 1H), 3.56 (ddd, *J* = 10.6, 7.1, 3.5 Hz, 1H), 2.45 (s, 3H), 1.80 – 1.65 (m, 4H), 1.51 (s, 1H), 1.44 – 1.35 (m, 4H), 1.22 – 1.11 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 153.2, 144.7, 138.5, 131.3, 130.0, 127.4, 42.4, 31.2, 25.3, 25.1, 21.6. IR (KBr, cm⁻¹): 2929, 2856, 2357, 1758, 1596, 1450, 1321, 1148, 1072, 813, 549; ESI-HRMS calcd for C₁₅H₁₉BrO₂S (M + Na)⁺ 365.0181; found, 365.0170.

(E)-1-(2-bromo-4-phenylbut-1-enylsulfonyl)-4-methylbenzene (3ao)

colorless oil (160.1 mg, 88%); ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 8.3 Hz, 2H), 7.32 – 7.23 (m, 7H), 6.72 (s, 1H), 3.39 (dd, *J* = 8.8, 6.7 Hz, 2H), 2.94 (dd, *J* = 8.7, 6.8 Hz, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.8, 144.7, 139.5, 137.9, 132.5, 130.0, 128.7, 128.6, 127.4, 126.5, 38.6, 34.6, 21.6. IR (KBr, cm⁻¹): 3046, 2358, 2170, 1604, 1419, 1271, 1148, 1078, 754, 545; ESI-HRMS calcd for C₁₇H₁₇BrO₂S (M + Na)⁺ 387.0025; found, 387.0027.

(E)-1-(1-bromo-2-(phenylsulfonyl)vinyl)benzene (3ba)¹

white solid (138.4 mg, 86%); mp 79–80 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, *J* = 8.3, 0.9 Hz, 2H), 7.54 (t, *J* = 7.5 Hz, 1H), 7.39 (t, *J* = 7.9 Hz, 3H), 7.34 – 7.29 (m, 4H), 7.17 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 140.4, 138.8, 136.0, 134.2, 133.5, 130.4, 129.0, 128.6, 128.0, 127.8.

(E)-1-(2-bromo-2-phenylvinylsulfonyl)-4-fluorobenzene (3ca)

white solid (142.8 mg, 84%); mp 87–89 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.57 (ddd, *J* = 8.1, 5.0, 2.5 Hz, 2H), 7.41 – 7.37 (m, 1H), 7.35 – 7.26 (m, 4H), 7.17 (s, 1H), 7.07 – 7.01 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 167.1, 164.3, 139.0, 136.3, 136.3, 135.9, 134.2, 132.7, 130.7, 130.6, 130.5, 128.5, 128.1, 116.3, 116.1. IR (KBr, cm⁻¹): 3047, 2960, 1605, 1321, 1150, 820, 651, 555; ESI-HRMS calcd for C₁₄H₁₀BrFO₂S (M + Na)⁺ 362.9461; found, 362.9453.

(E)-1-(2-bromo-2-phenylvinylsulfonyl)-4-chlorobenzene (4da)¹

white solid (142.4 mg, 80%); mp 116–118 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.59 – 7.55 (m, 2H), 7.42 – 7.34 (m, 2H), 7.33 – 7.28 (m, 3H), 7.17 (s, 1H), 7.07 – 7.02 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 139.0, 135.9, 134.3, 130.7, 130.6, 130.5, 128.6, 128.1, 116.3, 116.1.

(E)-1-bromo-4-(2-bromo-2-phenylvinylsulfonyl)benzene (3ea)¹

white solid (166.0 mg, 83%); mp 120–121 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.54 – 7.49 (m, 2H), 7.43 – 7.37 (m, 3H), 7.36 – 7.31 (m, 2H), 7.28 (dd, *J* = 5.3, 3.3 Hz, 2H), 7.15 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 139.4, 139.3, 135.9, 134.0, 132.2, 130.6, 129.3, 128.9, 128.5, 128.1.

(E)-2-(2-bromo-2-phenylvinylsulfonyl)naphthalene (3fa)

white solid (158.1 mg, 85%); mp 104–106 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 1.3 Hz, 1H), 7.86 (d, *J* = 8.6 Hz, 2H), 7.78 (d, *J* = 8.1 Hz, 1H), 7.66 – 7.60 (m, 2H), 7.59 – 7.54 (m, 1H), 7.32 – 7.19 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 138.8, 136.9, 135.9, 135.0, 134.3, 131.9, 130.4, 129.8, 129.3, 129.3, 129.3, 128.5, 127.9, 127.8, 127.5, 122.3. IR (KBr, cm⁻¹): 3046, 2367, 2158, 1615, 1420, 1272, 1148, 1080, 754, 545; ESI-HRMS calcd for C₁₈H₁₃BrO₂S (M + Na)⁺ 394.9712; found, 394.9710.

(E)-2-(2-bromo-2-phenylvinylsulfonyl)thiophene (3ga)

white solid (134.5 mg, 82%); mp 85–87 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (dd, *J* = 5.0, 1.3 Hz, 1H), 7.42 – 7.35 (m, 5H), 7.33 – 7.30 (m, 1H), 7.22 (s, 1H), 6.98 (dd, *J* = 4.9, 3.9 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 141.4, 139.0, 135.9, 134.4, 134.3, 134.2, 130.5, 128.5, 128.0, 127.6. IR (KBr, cm⁻¹): 3050, 2357, 1629, 1327, 1144, 1081, 1013, 872, 573; ESI-HRMS calcd for C₁₂H₉BrO₂S (M + Na)⁺ 350.9120; found, 350.9120.

(E)-1-(2-iodo-2-phenylvinylsulfonyl)-4-methylbenzene (4a)

white solid (168.9 mg, 88%); mp 90–92 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.3 Hz, 2H), 7.36 (s, 1H), 7.31 – 7.24 (m, 3H), 7.22 (dt, *J* = 8.2, 2.1 Hz, 2H), 7.17 (d, *J* = 8.0 Hz, 2H), 2.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 141.2, 139.6, 137.2, 129.7, 129.6, 127.8, 127.8, 127.6, 114.1, 21.5. IR (KBr, cm⁻¹): 3040, 2964, 16001, 1322, 1152, 823, 658, 556; ESI-HRMS calcd for C₁₅H₁₃IO₂S (M + Na)⁺ 406.9573; found, 406.9586.

(E)-1-chloro-4-(1-iodo-2-tosylvinyl)benzene (4b)

white solid (179.7 mg, 86%); mp 104–105 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 7.9 Hz, 2H), 7.35 (s, 1H), 7.30 – 7.17 (m, 4H), 6.97 (t, *J* = 8.4 Hz, 2H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 161.8, 144.7, 141.5, 137.1, 135.6, 135.6, 129.9, 129.8, 129.6, 127.7, 115.1, 114.8, 112.5, 21.5. IR (KBr, cm⁻¹): 3040, 2958, 1590, 1327, 1150, 828, 651, 555; ESI-HRMS calcd for C₁₅H₁₂ClIO₂S (M + Na)⁺ 440.9183; found, 440.9211.

(E)-1-fluoro-4-(1-iodo-2-tosylvinyl)benzene (4c)

white solid (178.9 mg, 89%); mp 97–98 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, *J* = 8.0 Hz, 2H), 7.35 (s, 1H), 7.28 – 7.18 (m, 4H), 6.97 (t, *J* = 8.5 Hz, 2H), 2.39 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.0 (d, *J* = 294.8), 144.7, 141.5, 137.1, 135.6 (d, *J* = 3.4), 129.9 (d, *J* = 8.6), 129.6, 127.6, 115.0 (d, *J* = 2.2), 112.5, 21.5. IR (KBr, cm⁻¹): 3038, 2954, 1587, 1326, 1153, 827, 652, 558; ESI-HRMS calcd for C₁₅H₁₂FIO₂S (M + Na)⁺ 424.9478; found, 424.9475.

(E)-1-(1-iodo-2-tosylvinyl)-3,5-bis(trifluoromethyl)benzene (4d)

white solid (226.2 mg, 87%); mp 107–108 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.60 (s, 2H), 7.51 (s, 1H), 7.44 (d, *J* = 8.1 Hz, 2H), 7.22 (d, *J* = 8.0 Hz, 2H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 145.49, 144.03, 141.55, 136.62, 131.5 (q, *J* = 33.7 Hz), 129.99, 127.7 (d, *J* = 3.6 Hz), 127.65, 122.7 (d, *J* = 271.3 Hz), 123.2 (m), 107.69, 21.51. IR (KBr, cm⁻¹): 3042, 2948, 1592, 1328, 1150, 828, 651, 556; ESI-HRMS calcd for C₁₅H₁₂ClF₃O₂S (M + Na)⁺ 542.9320; found, 542.9324.

(2-tosylethene-1,1-diyl)dibenzene (5a)²

colorless oil (74.3 mg, 89%); ¹H NMR (400 MHz, CDCl₃) δ 7.90 – 7.88 (m, 2H), 7.47 (d, *J* = 8.2 Hz, 2H), 7.36 (dt, *J* = 7.0, 6.3 Hz, 4H), δ 7.20 (dd, *J* = 5.3, 3.4 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 7.09 (dd, *J* = 5.2, 3.3 Hz, 2H), 6.99 (s, 1H), 2.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.6, 143.7, 139.2, 138.6, 135.5, 130.2, 129.7, 129.3, 128.9, 128.8, 128.5, 128.1, 127.7, 127.6, 21.47.

(E)-(4-tosylbut-3-en-1-yne-1,3-diyl)dibenzene (5b)

white solid (80.6 mg, 90%); mp 96–97 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J* = 8.0 Hz, 2H), 7.52 (d, *J* = 7.1 Hz, 2H), 7.47 – 7.33 (m, 8H), 7.22 (d, *J* = 7.9 Hz, 2H), 6.99 (s, 1H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.2, 137.9, 136.7, 135.3, 134.1, 131.8, 129.5, 129.4, 129.4, 128.9, 128.4,

127.8, 127.6, 121.4, 97.3, 88.3, 21.4. IR (KBr, cm^{-1}): 3046, 2961, 1601, 1320, 1149, 828, 651, 555; ESI-HRMS calcd for $\text{C}_{23}\text{H}_{18}\text{O}_2\text{S}$ ($\text{M} + \text{Na}$)⁺ 381.0920; found, 381.0920.

(E)-1-methyl-4-(styrylsulfonyl)benzene (6a)²

colorless oil (103.2 mg, 80%); ¹H NMR (400 MHz, CDCl_3) δ 7.83 (d, J = 8.3 Hz, 2H), 7.65 (d, J = 15.4 Hz, 1H), 7.49 – 7.45 (m, 2H), 7.42 – 7.36 (m, 3H), 7.34 (d, J = 8.0 Hz, 2H), 6.85 (d, J = 15.4 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl_3) δ 144.3, 141.9, 137.7, 132.4, 131.0, 129.9, 129.0, 128.5, 127.7, 127.6, 21.55.

Reference:

1. Taniguchi, N. *Synlett* **2012**, 1245.
2. Li, X.; Shi, X.; Fang, M.; Xu, X. *J. Org. Chem.*, **2013**, 78, 9499.

NMR Spectra for Compounds 3aa-3ga, 4a-6a

